发明公开
EP3177597A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS
审中-公开
2-氨基 - 苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素E合成酶抑制剂的用途
- 专利标题: 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS
- 专利标题(中): 2-氨基 - 苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素E合成酶抑制剂的用途
-
申请号: EP15748009.6申请日: 2015-07-31
-
公开(公告)号: EP3177597A1公开(公告)日: 2017-06-14
- 发明人: KIM, Jaeseung , AHN, Seohyun , JEON, Yeejin , PARK, Dongsik , YANG, Young-In , LEE, Doohyung , LEE, SaeYeon , AHN, Jiye , KIM, Jeongjun , NAM, Kiyean , KANG, Sunhee , SEO, MinJung , SEO, Mooyoung , SEO, Jeongjea , HAN, Sung-Jun , KIM, Jung Hwan , LEE, Sangchul , CHOI, Gahee , LEE, Yunmi
- 申请人: Institut Pasteur Korea , Qurient Co. Ltd.
- 申请人地址: 16 Daewangpangyo-ro 712beon-gil Bundang-gu Seongnam-si, Gyeonggi 463-400 KR
- 专利权人: Institut Pasteur Korea,Qurient Co. Ltd.
- 当前专利权人: Institut Pasteur Korea,Qurient Co. Ltd.
- 当前专利权人地址: 16 Daewangpangyo-ro 712beon-gil Bundang-gu Seongnam-si, Gyeonggi 463-400 KR
- 代理机构: Engelhard, Markus
- 优先权: US201462031337P 20140731
- 国际公布: WO2016016421 20160204
- 主分类号: C07D235/20
- IPC分类号: C07D235/20 ; C07D401/04 ; C07D401/06 ; C07D401/12 ; C07D401/14 ; C07D403/04 ; C07D403/12 ; C07D403/14 ; C07D405/12 ; C07D405/14 ; C07D409/14 ; C07D413/12 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; A61K31/4184
摘要:
The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, -NH2, -NHR6, -NR7R8 and -NH-(R9)n-R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, -NH2, -NHR6, - NR7R8 and -NH-(R9)n-R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, -NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, -C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of -NH2, -N(R12)(V)pR13, - NH(V)p-OR14, -NHC(O)R15, and groups of formula la shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease.
公开/授权文献
信息查询